An evaluation of a Myomscore in the preoperative assessment of uterus myomatosus: a new diagnostic standard? The experience at the Mathilden Hospital in Herford, Germany

Wojdat, R.; Malanowska, Ewelina

doi:10.1186/s10397-020-01074-3

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All extirpating procedures used for hysterectomy, whether performed with laparotomy or laparoscopy, involve the risk of disseminating malignant cells in the abdominal cavity. However, gentle surgery, without unnecessary manipulations and without injury to the uterine surface, could significantly reduce this risk [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Retrospective Analysis of Cervical Cancer Treatment Outcomes: Ten Years of Experience with the Vaginal Assisted Radical Laparoscopic Hysterectomy VARLH

Wojdat

Malanowska

2022

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Background. LACC trial demonstrated inferiority of laparoscopic approach for the treatment of early-stage cervical cancer. There are still limited data from retrospective trials regarding whether survival outcomes after laparoscopic radical hysterectomy are equivalent to those after open abdominal radical hysterectomy. In this study, we present results of combined vaginal radical laparoscopic hysterectomy in the treatment of early-stage cervical cancer. Methods. This retrospective study was carried out at the Department of Gynecology in Mathilden Hospital (Herford, Germany). Between January 2008 and April 2018, all the patients with invasive cervical cancer who underwent combined vaginal assisted radical laparoscopic hysterectomy (VARLH) without the use of any uterine manipulator were enrolled to the study. Results. A total number of 124 patients with diagnosis of invasive cervical cancer were enrolled in the study. All of the patients underwent minimally invasive surgery and were divided according to FIGO 2019: stage IA (25.9%), IB1 (25.0%), IB2-IIB (28.4%), and III/IV (20.7%). Overall, the mean age of the patients was 51.84 years. After a study collection, a median follow-up was 45.6 (range 23.7-76.5) months. The 3- and 5-year disease-free survival rates for early-stage cervical cancer were both 98%, and the 3- and 5-year overall survival rates were 100% and 97%, respectively. We have not observed any recurrence in our study group of patients with early-stage cervical cancer. Conclusions. Combined VARLH can be considered a safe and effective procedure for the treatment of early-stage cervical cancer. Surgical strategy with oncological principles determines the quality and long-term success of the operation in early cervical cancer regardless of laparoscopic approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective Analysis of Cervical Cancer Treatment Outcomes: Ten Years of Experience with the Vaginal Assisted Radical Laparoscopic Hysterectomy VARLH

Wojdat

Malanowska

2022

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Each test has varying degrees and ranges of accuracy-endometrial biopsy, 58-64% [17,18]; pelvic ultrasonography, 11-56%; pelvic MRI, 35.3-80% [19,20]; lactate dehydrogenase (LDH); and sensitivity, 0.47 [21]. The use of these tests in combination with patient demographics, such as age and menopausal status, has been proposed for use independently or as part of an algorithm to determine a "preoperative risk score" for uterine tumors [7,[21][22][23]. Although some of these evaluative tools show promise, their reported testing properties must be interpreted cautiously based on the generalizability of the studies to the population at large [24].…”

Section: Challenges With Differentiating Uterine Leiomyoma From Uteri...mentioning

confidence: 99%

“…The immune cell composition in uLMS consists of several immunosuppressive cell populations, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) [12,14,21]. These immunosuppressive cells are critical for conferring resistance to ICB [22] and mediating immune escape from cancers [96]. Evidence indicates that tumor-intrinsic pathways, including the PI3K/mTOR pathway, Wnt/β-catenin pathway, VEGF/VEGFR, and receptor tyrosine kinases, are critical in regulating the immune response.…”

Section: Immune Checkpoint Blockadementioning

confidence: 99%

Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy

Yang,

Madueke-Laveaux,

Cun

et al. 2024

Cells

View full text Add to dashboard Cite

Uterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas. They have a poor prognosis with high rates of recurrence and metastasis. The five-year survival for uLMS patients is between 25 and 76%, with survival rates approaching 10–15% for patients with metastatic disease at the initial diagnosis. Accumulating evidence suggests that several biological pathways are involved in uLMS pathogenesis. Notably, drugs that block abnormal functions of these pathways remarkably improve survival in uLMS patients. However, due to chemotherapy resistance, there remains a need for novel drugs that can target these pathways effectively. In this review article, we provide an overview of the recent progress in ascertaining the biological functions and regulatory mechanisms in uLMS from the perspective of aberrant biological pathways, including DNA repair, immune checkpoint blockade, protein kinase and intracellular signaling pathways, and the hedgehog pathway. We review the emerging role of epigenetics and epitranscriptome in the pathogenesis of uLMS. In addition, we discuss serum markers, artificial intelligence (AI) combined with machine learning, shear wave elastography, current management and medical treatment options, and ongoing clinical trials for patients with uLMS. Comprehensive, integrated, and deeper insights into the pathobiology and underlying molecular mechanisms of uLMS will help develop novel strategies to treat patients with this aggressive tumor.

show abstract

An evaluation of a Myomscore in the preoperative assessment of uterus myomatosus: a new diagnostic standard? The experience at the Mathilden Hospital in Herford, Germany

Cited by 2 publications

References 19 publications

Retrospective Analysis of Cervical Cancer Treatment Outcomes: Ten Years of Experience with the Vaginal Assisted Radical Laparoscopic Hysterectomy VARLH

Retrospective Analysis of Cervical Cancer Treatment Outcomes: Ten Years of Experience with the Vaginal Assisted Radical Laparoscopic Hysterectomy VARLH

Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy

Contact Info

Product

Resources

About